← Leaderboards
Gauri G Rao
Univ Of North Carolina Chapel Hill
$3,917,013
Attributed
$9,213,724
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,363,724 · 3
FDA$850,000 · 1
By mechanism
R01$8,363,724 · 3
U01$850,000 · 1
Top collaborators
- Tony Velkov11 shared
- Charles Richard Esther3 shared
- Martina Gentzsch3 shared
- Sara Elizabeth Maloney3 shared
- Miriam S. Braunstein2 shared
- Keith S Kaye1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- David S Weiss$16,596,967
- Joseph J. Eron$450,672,292
- Pilar Blancafort$2,741,152
- Chris Whitfield$920,606
- Qisheng Zhang$4,632,517
Others in their field
Other Emerging Leaders on “Pharmacokinetics And Pharmacodynamics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$235,521,096
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,585,966
- John Damon Chodera · Sloan-Kettering Inst Can Research$25,066,508
- Gary Fanger · Rise Therapeutics, Llc$15,733,133
- Xinhua Li · Nano Terra, Inc.$14,470,585
Research focus
Pharmacokinetics And PharmacodynamicsBacteriaAntibioticsPharmacologyInfectionRegimenDrug KineticsPharmacodynamicsAntibiotic TherapyInnovationHospitalsInternationalAntimicrobial ResistanceRattusMedicalDisease OutbreaksDosageAntibiotic ResistanceDangerousnessCostAcinetobacter BaumanniiPathogenPseudomonas AeruginosaResistance
Grant awards (16)
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$1,663,595
R01 · FY2025 · AI · contact PI
In vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infection$764,080
R01 · FY2025 · AI
In vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infection$816,995
R01 · FY2024 · AI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$732,598
R01 · FY2024 · AI · contact PI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$548,207
R01 · FY2023 · AI · contact PI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$344,692
R01 · FY2023 · AI · contact PI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$274,311
R01 · FY2023 · AI · contact PI
A physiologically based pharmacokinetic model of human airway epithelia$250,000
U01 · FY2023 · FD
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$184,555
R01 · FY2023 · AI · contact PI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$676,074
R01 · FY2022 · AI · contact PI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$625,436
R01 · FY2022 · AI · contact PI
A physiologically based pharmacokinetic model of human airway epithelia$300,000
U01 · FY2022 · FD
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$572,813
R01 · FY2021 · AI · contact PI
A physiologically based pharmacokinetic model of human airway epithelia$300,000
U01 · FY2021 · FD
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$562,520
R01 · FY2020 · AI · contact PI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$597,848
R01 · FY2019 · AI · contact PI